Tharimmune rises after US FDA backs opioid overdose prevention drug plan

Canton Strategic Holdings

13/11/2025 13:38

** Shares of drug-developer Tharimmune THAR.O rise 1.58% to $3.24 premarket

** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids

** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR

** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR

** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's <2 hrs

** Up to last close, stock up ~59% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))